Zobrazeno 1 - 10
of 188
pro vyhledávání: ''
Autor:
Albert C. Lockhart, Andrea Wang-Gillam, Michael J. Naughton, Joel Picus, Rama Suresh, Feng Gao, Gretel Terrero, Maria Q. Baggstrom, Lauren Trull, Cynthia Ma, Paula M. Fracasso, Benjamin R. Tan, Manik Amin, Stephanie Belanger
Publikováno v:
American Journal of Clinical Oncology. 44:443-448
Introduction The mammalian target of rapamycin (mTOR) is a downstream mediator in the phosphatidylinositol 3-kinase/Akt signaling pathway, and plays a central role in cell proliferation, growth, differentiation, migration, and survival. Temsirolimus
Publikováno v:
American Journal of Clinical Oncology. 43:496-503
OBJECTIVES The value of adjuvant chemotherapy in T2N0M0 non-small-cell lung cancer (NSCLC) is unclear. Some current guidelines suggest adjuvant chemotherapy be considered for patients with tumors ≥4 cm. Prior population-based evaluations lacked lun
Autor:
Asad Javed, Svetomir N. Markovic, Lori A. Erickson, Vera J. Suman, Marc S. Ernstoff, Daniel M. Anderson, Darci J. Wall, Joel M. Reid
Publikováno v:
American Journal of Clinical Oncology. 43:115-121
Objectives With the introduction of novel immune therapeutics for the treatment of disseminated malignancies, we sought to evaluate whether deliberate sequencing of immunotherapy before/after conventional cytotoxic chemotherapy would have an impact o
Autor:
Nan Zhang, Alyx B. Porter, Luke Mountjoy, Jonathan B. Ashman, Terence T. Sio, Akanksha Sharma, Maciej M. Mrugala, Naresh P. Patel, Richard J. Butterfield, Richard S. Zimmerman, Steven E. Schild, Sujay A. Vora, Helen J. Ross, Harshita Paripati, Thomas B. Daniels
Publikováno v:
American Journal of Clinical Oncology. 43:128-132
Objective Radiation therapy (RT) is the primary treatment of intracranial metastasis (ICM) from lung cancer (LC). Radiation necrosis (RN) has been reported post-RT with an incidence of 5% to 24%. We reviewed the spectrum of imaging changes in patient
Autor:
Christie Farrer, Winson Y. Cheung, Natalie Devost, Dimas Yusuf, R. Walton, M. Hurry, Atul Batra
Publikováno v:
American journal of clinical oncology. 44(10)
Background Treatment strategies for metastatic non-small cell lung cancer (NSCLC) are evolving rapidly and can be highly variable. Real-world evidence of treatment patterns and outcomes can provide an understanding of our current practice and offer i
Autor:
Mi Hyun Kim, Tae-Won Jang, Min Ki Lee, Kyeong Choel Shin, Choonhee Son, Hyun Kyung Lee, Hyun-Kuk Kim, Jung Seop Eom, Jiyeon Roh, Seong Hoon Yoon, Shin Yup Lee, Jehun Kim
Publikováno v:
American journal of clinical oncology. 44(7)
Objectives Immune checkpoint inhibitors (ICIs) targeting the programmed cell death receptor-1 and its ligand have achieved impressive success in treating patients with advanced-stage non-small cell lung cancer (NSCLC) after failed first-line cytotoxi
Autor:
Jan Jenkins, Dana Sharma, Raj Singh, Hayden Ansinelli, Sanjeev Sharma, John A. Vargo, Joanne Davis
Publikováno v:
American Journal of Clinical Oncology. 42:602-606
Objectives To utilize the RSSearch Patient Registry (RSSPR) to examine local control (LC), overall survival (OS), and toxicities following stereotactic body radiation therapy (SBRT) for stage I (T1-T2/N0) medically inoperable small cell lung carcinom
Autor:
Tomoya Kawaguchi, Kazuto Hirata, Tatsuo Kimura, Naoki Yoshimoto, Shinzoh Kudoh, Shigeki Mitsuoka, Naruo Yoshimura, Tomohiro Tamiya, Kenji Sawa, Takuhito Tada, Yoshiya Matsumoto, Tomohiro Suzumura, Masako Hosono, Tomonori Hirashima, Hidenori Tanaka
Publikováno v:
American Journal of Clinical Oncology. 41:967-971
A phase I study to determine a recommended dose of thoracic radiotherapy using accelerated hyperfractionation for unresectable non-small cell lung cancer was conducted.We used chemotherapy of a cisplatin doublet and 2 dose levels of radiation with ac
Publikováno v:
American journal of clinical oncology. 43(5)
Small cell lung cancer (SCLC) is an aggressive disease treated as soon as possible given its rapid doubling time. Evidence for the appropriate time to chemotherapy initiation (TCI) for SCLC is lacking. This study evaluated TCI in SCLC on a national l
Autor:
Jorge Gomez, Marcelo Bonomi, Keith Sigel, Grace Mhango, Cardinale B. Smith, Minal Kale, Juan P. Wisnivesky
Publikováno v:
American Journal of Clinical Oncology. 40:470-476
Toxicity is a main concern limiting the use of chemotherapy and radiotherapy (RT) for elderly patients with non-small cell lung cancer (NSCLC). The objective of this study was to assess the rates of treatment-related toxicity among elderly stage IIIB